- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ASARINA PHARMA Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ARCUTIS BIOTHERAPEUTICS | 21,110 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis' ZORYVE (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines | Strong recommendation with high certainty of clinical evidence underscores proven efficacy, safety, and tolerability of ZORYVE cream as a steroid-free topical phosphodiesterase type 4 (PDE4) inhibitorAtopic... ► Artikel lesen | |
| NUVALENT | 104,95 | 0,00 % | Nuvalent, Inc.: Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting | Presentation of pivotal data for neladalkib in TKI pre-treated patients with advanced ALK-positive NSCLC from ALKOVE-1 trial
TKI pre-treated data from ALKOVE-1 trial... ► Artikel lesen | |
| CG ONCOLOGY | 61,83 | -0,10 % | CG Oncology, Inc. - 8-K, Current Report | ||
| KYMERA THERAPEUTICS | 80,77 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma | KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast Track... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,000 | 0,00 % | Bernstein reiterates Summit Therapeutics stock Underperform rating | ||
| RECURSION PHARMACEUTICALS | 2,965 | -0,17 % | Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now? | ||
| IMMUNOVANT | 33,850 | +0,06 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 350,43 | -0,05 % | H.C. Wainwright reiterates Praxis Precision stock rating on patent news | ||
| IMMUNOME | 21,910 | 0,00 % | What Offers Immunome (IMNM) a Compelling Investment Opportunity? | ||
| ARRIVENT BIOPHARMA | 27,940 | 0,00 % | Cantor Fitzgerald bestätigt "Overweight"-Rating für ArriVent-Aktie | ||
| TRAVERE THERAPEUTICS | 44,300 | +0,02 % | Travere Therapeutics, Inc. - 8-K, Current Report | ||
| COGENT BIOSCIENCES | 33,980 | +0,12 % | Cogent Biosciences: Aktie legt vor wichtigen Studiendaten um 4 % zu | ||
| ALUMIS | 22,330 | 0,00 % | Alumis Inc.: Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality-of-life improvements and itch... ► Artikel lesen | |
| ERASCA | 11,525 | +0,22 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| IMMIX BIOPHARMA | 8,830 | -0,11 % | Immix Biopharma, Inc.: Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2 | - Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) - - CR rate now 95% (19 of 20 patients) - - All CRs reached within 1 year of follow-up post-dosing... ► Artikel lesen |
ASARINA PHARMA AB gehört der Branche Biotechnologie an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ASARINA PHARMA AB finden Sie auf Wallstreet Online.